Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
As countries reopen businesses and move toward normalcy, emerging biotech companies in the U.S. and Europe have encountered a mixed bag of experiences.
As of June 29, there were 13 vaccines against COVID-19 in human clinical trials.
In a forthcoming paper, 239 scientists from more than 30 countries are pushing the World Health Organization to pay more attention to the possible airborne spread of SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
By using the herpes simplex virus (HSV) as a helper for its adeno-associated viral (AAV) platform, Applied Genetic Technologies Corporation (AGTC) created AAVs that are more robust, purer and lower cost than any of the other methods.
Massachusetts-based Amylyx Pharmaceuticals, a company focused on developing new treatments for neurodegenerative diseases, announced today that it had concluded a $30 million Series B round of financing.
Moderna has always been an odd and secretive company. Currently all eyes are on the company because it is the furthest along in developing a vaccine against COVID-19.